News
Sanofi, Regeneron prep filings for Libtayo in cervical cance...
Sanofi and Regeneron’s checkpoint inhibitor Libtayo has become the first immunotherapy to improve survival when used as a second-line therapy in cervical cancer, setting up regulatory filin
